10-Q: INVO Bioscience Reports Increased Revenue Driven by Clinic Acquisitions in Q2 2024
Sentiment:
Quarterly Report
INVO Bioscience saw a significant revenue increase in the second quarter of 2024, primarily due to the acquisition of the Wisconsin Fertility Institute.
Capital raiseThe company is dependent on raising capital from debt and equity financings to meet its cash needs.The company will seek debt and/or equity funding, which may not be available on reasonable terms, if at all.The company is in negotiations with NAYA to further amend the Merger Agreement and the Series A Preferred SPA.
Better than expectedThe company's revenue significantly increased due to the acquisition of the Wisconsin Fertility Institute.
Summary
- INVO Bioscience reported a revenue of $1.8 million for the three months ended June 30, 2024, a substantial increase from $0.3 million in the same period of 2023.
- The revenue growth was primarily driven by clinic revenue from the Wisconsin Fertility Institute (WFI) acquisition and the Georgia joint venture.
- Operating expenses increased to $3.7 million for the quarter, up from $2.4 million in the prior year, due to higher costs of revenue and selling, general, and administrative expenses.
- The company reported a net loss of $2.2 million for the quarter, compared to a net loss of $2.2 million in the same period last year.
- For the six months ended June 30, 2024, revenue was $3.4 million, compared to $0.7 million for the same period in 2023.
- The net loss for the first six months of 2024 was $3.8 million, compared to $4.8 million for the same period in 2023.
- The company's cash balance increased to $0.9 million as of June 30, 2024, from $0.2 million at the end of 2023.
- The company has an accumulated deficit of $61.9 million as of June 30, 2024.
Sentiment
Score: 6
Explanation: The document shows significant revenue growth due to acquisitions, but the company is still operating at a loss and has a going concern qualification. The company is also facing potential delisting from Nasdaq. The sentiment is therefore cautiously optimistic.
Positives
- The acquisition of the Wisconsin Fertility Institute significantly boosted revenue.
- The company's cash balance improved to $0.9 million.
- The company's six month net loss decreased from $4.8 million to $3.8 million.
Negatives
- The company continues to operate at a loss, with a net loss of $2.2 million for the quarter.
- Operating expenses remain high at $3.7 million for the quarter.
- The company has an accumulated deficit of $61.9 million.
Risks
- The company is dependent on raising capital from debt and equity financings to meet its cash needs.
- The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
- The company is subject to various covenants that restrict its ability to declare dividends, make certain investments, sell assets outside the ordinary course of business, or enter into transactions with affiliates.
- The company is currently not in compliance with Nasdaq listing rules and may be delisted.
Future Outlook
The company plans to grow the Wisconsin Fertility Institute and pursue additional IVF clinic acquisitions. The company also plans to pursue the merger with NAYA Biosciences, Inc. The company will need to raise additional funding to meet its liquidity needs and to execute its business strategy.
Industry Context
The global ART market is experiencing growth due to increased infertility rates, patient awareness, and acceptance of treatment options. INVO Bioscience is positioning itself to capitalize on this growth through its clinic operations and INVOcell technology. The company is also addressing the industry's capacity constraints and cost barriers by offering a lower-cost alternative to traditional IVF.
Comparison to Industry Standards
- The company's revenue growth is significant compared to previous periods, primarily due to the acquisition of WFI, which is a positive sign.
- The company's net losses are still substantial, indicating that it is not yet profitable, which is not uncommon for companies in the growth phase.
- The company's cash balance has improved, but it still relies on external funding, which is a risk factor.
- The company's strategy of acquiring existing IVF clinics is a common approach in the industry to achieve rapid growth and scale.
- The company's INVOcell technology offers a lower-cost alternative to traditional IVF, which could be a competitive advantage.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director of WFRSA | Dr. Elizabeth Pritts, M.D. | Donna Baldwin, D.O. | 2024-06-13 | Separation of employment |
Related Party Transactions
- The company issued a series of demand promissory notes in the aggregate principal amount of $550,000 to a related party, JAG.
- The company issued demand promissory notes in the aggregate principal amount of $220,000 to its Chief Executive Officer and an entity controlled by its Chief Financial Officer.
Stakeholder Impact
- Shareholders face the risk of losing their investment if the company cannot continue as a going concern.
- Employees may be affected by the company's financial instability.
- Customers may benefit from the company's lower-cost fertility treatment options.
- Creditors face the risk of non-payment if the company's financial situation does not improve.
Next Steps
- The company plans to grow the Wisconsin Fertility Institute.
- The company plans to pursue additional IVF clinic acquisitions.
- The company plans to pursue the merger with NAYA Biosciences, Inc.
- The company is evaluating various courses of action to regain compliance with Nasdaq listing rules.
Key Dates
| Date | Description |
|---|---|
| 2015-11 | INVOcell received FDA clearance for marketing and use in the United States. |
| 2019-10 | INVO Bioscience received the CE Mark. |
| 2020-09-24 | INVO CTR entered into a Pre-Incorporation and Shareholders Agreement to establish Positib Fertility, S.A. de C.V. (the Mexico JV). |
| 2021-03-10 | INVO CTR entered into a limited liability company agreement with HRCFG, LLC to establish HRCFG INVO, LLC (the Alabama JV). |
| 2021-06-28 | INVO CTR entered into a limited liability company agreement with Bloom Fertility, LLC to establish Bloom INVO LLC (the Georgia JV). |
| 2021-08-09 | The Birmingham clinic opened to patients. |
| 2021-09-07 | The Atlanta Clinic opened to patients. |
| 2021-11-01 | The Monterrey Clinic opened to patients. |
| 2023-02-03 | The company entered into securities purchase agreements for the purchase of convertible debentures. |
| 2023-03-23 | INVO entered into a securities purchase agreement for a registered direct offering. |
| 2023-06 | INVO received FDA 510(k) clearance to expand the labeling on the INVOcell device. |
| 2023-06-28 | The company's board of directors approved a reverse stock split. |
| 2023-07-28 | The company effectuated a 1-for-20 reverse stock split. |
| 2023-08-04 | The company entered into securities purchase agreements for a public offering. |
| 2023-08-10 | INVO consummated the acquisition of the Wisconsin Fertility Institute. |
| 2023-09-29 | The company entered into a Revenue Loan and Security Agreement. |
| 2023-10-13 | Stockholders approved an increase to the number of authorized shares of common stock. |
| 2023-10-22 | The company entered into a Merger Agreement with NAYA Biosciences, Inc. |
| 2023-11-19 | The company entered into a share exchange agreement with Cytovia Therapeutics Holdings, Inc. |
| 2023-11-20 | The company filed a Certificate of Designation of Series A and Series B Convertible Preferred Stock. |
| 2023-12-27 | The company extended the maturity date of the Q1 2023 Convertible Notes to June 30, 2024. |
| 2023-12-29 | The company entered into a securities purchase agreement with NAYA for the purchase of Series A Preferred Stock. |
| 2024-01-04 | The company and NAYA closed on the first tranche of Series A Preferred Stock. |
| 2024-02-26 | The company finalized an Agreement for the Purchase and Sale of Future Receipts. |
| 2024-03-27 | The company entered into a purchase agreement with Triton Funds LP. |
| 2024-04-05 | The company entered into a purchase agreement with FirstFire Global Opportunities Fund, LLC. |
| 2024-04-17 | The company reduced the exercise price of the August 2023 Warrants. |
| 2024-04-19 | INVO CTR completed the assignment of its lease for the Tampa Premises. |
| 2024-05-01 | The company entered into a third amendment to the Merger Agreement. |
| 2024-06-13 | Wood Violet caused the transfer of ownership of WFRSA. |
| 2024-06-28 | The company extended the maturity date of the Q1 2023 Convertible Notes to December 31, 2024. |
Keywords
INVO Bioscience, fertility, IVF, INVOcell, clinic acquisition, revenue growth, financial results, healthcare services, Wisconsin Fertility Institute, joint ventures
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.